Slide

July 15, 2025 – Aptar Pharma, a global leader in drug delivery systems, services and active material science solution, announces its acquisition of the clinical trial materials manufacturing capabilities of MOD3 Pharma from SWK Holdings.

Slide

July 15, 2025 – Aptar Pharma, a global leader in drug delivery systems, services and active material science solution, announces its acquisition of the clinical trial materials manufacturing capabilities of MOD3 Pharma from SWK Holdings.

Risk. Time. Cost. The trifecta of challenges that can keep you awake at night. Because your project matters – it really matters, not just to you, but to the patients that will rely on your therapy to make their lives better.

Navigating the supply of your drug product for early phase clinical trials requires a team of scientists with a passion for drug development and the creativity to solve problems decisively. You need a team behind you that have seen it and done it before. Many times before.

At MOD3 Pharma, our seasoned experts start brilliantly with the end in mind, using a stage-appropriate framework to answer every complex element within Module 3. Together, we will transform your project into a clinic-ready proposition.

SCHEDULE A MEETING

We really want to talk to you about your next OINDP product. 
Let us be your catalyst to clinic.

Ask Us a Question

Our team relish finding answers to questions that  haven’t been thought of yet.

CONTACT US

Scroll to Top